We have located links that may give you full text access.
Aspartic acid functionalized PEGylated MSN@GO hybrid as an effective and sustainable nano-system for in-vitro drug delivery.
Advances in Medical Sciences 2018 March 21
PURPOSE: In this research, aspartic acid functionalized PEGylated mesoporous silica nanoparticlesgraphene oxide nanohybrid (As-PEGylated-MSN@GO) prepared as a pH-responsive drug carrier for the curcumin delivery. For better camouflage during blood circulation, poly(ethylene glycol) was decorated on the surface of MSN@GO nanohybrid.
MATERIALS AND METHODS: The nanocarrier was characterized by using X-ray powder diffraction (XRD), dynamic light scattering (DLS), UV-vis spectroscopy, thermal gravimetry analysis (TGA), FT-IR, SEM and TEM.
RESULTS: The size of modified MSN@GO was around 75.8 nm and 24% wt. of curcumin was loaded on the final nanohybrid. pHdecrement from 7.4 to 5.8 the release medium led to increase the cumulative amount of drug release from 54% to 98%.
CONCLUSIONS: As-functionalized MSN@GO had no cytotoxicity against human breast adenocarcinoma (MCF-7) and human mammary epithelial (MCF10A) as cancerous and normal cell lines, respectively. Whereas curcuminloaded nanohybrid showed excellent killing capability against MCF-7 cells.
MATERIALS AND METHODS: The nanocarrier was characterized by using X-ray powder diffraction (XRD), dynamic light scattering (DLS), UV-vis spectroscopy, thermal gravimetry analysis (TGA), FT-IR, SEM and TEM.
RESULTS: The size of modified MSN@GO was around 75.8 nm and 24% wt. of curcumin was loaded on the final nanohybrid. pHdecrement from 7.4 to 5.8 the release medium led to increase the cumulative amount of drug release from 54% to 98%.
CONCLUSIONS: As-functionalized MSN@GO had no cytotoxicity against human breast adenocarcinoma (MCF-7) and human mammary epithelial (MCF10A) as cancerous and normal cell lines, respectively. Whereas curcuminloaded nanohybrid showed excellent killing capability against MCF-7 cells.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app